insulin degludec/liraglutide (Xultophy®)

Insulin degludec/liraglutide (Xultophy®) is recommended as an option for restricted use within NHS Wales. Insulin degludec/liraglutide (Xultophy®) is licensed for the treatment of adults with type 2 diabetes mellitus to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or combined with a glucagon-like peptide protein-1 (GLP-1) receptor agonist or basal insulin do not provide adequate glycaemic control. Insulin degludec/liraglutide (Xultophy®) is restricted for use in combination with oral glucose-lowering medicinal products when these combined with basal insulin do not provide adequate glycaemic control. Insulin degludec/liraglutide (Xultophy®) is not recommended for use within NHS Wales outside of this subpopulation.